Viking Therapeutics Inc (VKTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.73B
Last updated: Nov 17, 2026 at 4:43 PM ET
Viking Therapeutics Inc (VKTX) Stock Chart
Viking Therapeutics (VKTX) has a latest price of $26.88 on Nov 17, 2026, 37.6% below its 52-week high of $43.10. Its price fell 31.3% over the past 12 months. The month-end price rose 2,449.5% over the 10 years through Oct 2026, a compound annual rate of 38.2%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $82.00 in Mar 2024 and its lowest $1.04 in Aug 2017, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart VKTX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for VKTX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 25.3%, and over 6 months it fell 5.4%. The month-end price rose 178.1% over the 3 years through Oct 2026, a compound annual rate of 40.6%.
| Period | Change |
|---|---|
| 1 month | +7.3% |
| 3 months | -25.3% |
| 6 months | -5.4% |
| 12 months | -31.3% |
| 12 months, with dividends | -31.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +178.1% | +40.6% |
| 5 years | +368.7% | +36.2% |
| 10 years | +2,449.5% | +38.2% |
Price by Year
Its best calendar year was 2017, when the price rose 241.2%, and its weakest was 2020, when it fell 29.8%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $27.28 | -22.5% |
| 2025 | $35.18 | -12.6% |
| 2024 | $40.24 | +116.2% |
| 2023 | $18.61 | +98.0% |
| 2022 | $9.40 | +104.3% |
| 2021 | $4.60 | -18.3% |
| 2020 | $5.63 | -29.8% |
| 2019 | $8.02 | +4.8% |
| 2018 | $7.65 | +88.4% |
| 2017 | $4.06 | +241.2% |
Trading Range
The price is 7.4% below its 50-day average of $29.03 and 16.4% below its 200-day average of $32.14.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $26.88 | |
| 52-week high | $43.10 | -37.6% |
| 52-week low | $23.82 | +12.8% |
| 50-day average | $29.03 | -7.4% |
| 200-day average | $32.14 | -16.4% |
Price Risk
Over 3 years, its largest fall from a peak was 78.9%.
| Measure | Value |
|---|---|
| 1-year beta | 1.36 |
| Largest fall, 1 year | -42.5% |
| Largest fall, 3 years | -78.9% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About VKTX
What is VKTX's 1-year price change?
Viking Therapeutics's price fell 31.3% over the past 12 months. With dividends included, the 12-month total return was -31.3%.
What is VKTX's 5-year price change?
Viking Therapeutics's month-end price rose 368.7% over the 5 years through Oct 2026, a compound annual rate of 36.2%. These figures leave out dividends.
What is VKTX's 52-week high and low?
Viking Therapeutics's 52-week high is $43.10 and its 52-week low is $23.82. Its latest price of $26.88 on Nov 17, 2026 is 37.6% below the high.
What is VKTX's beta?
Viking Therapeutics's 1-year beta against the S&P 500 is 1.36, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 42.5%.
Is the VKTX chart free?
Yes. Advanced Charting for VKTX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
VKTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors